Managed Healthcare Executive

CONTINUE TO SITE >

OR WAIT 15 SECS

AMCPAutoimmune DiseasesBiosimilarsCardiovascular DiseasesEyecareHow to Reduce Maternal, Infant Health Risks During COVID-19Improving Ophthalmic Care Access and Treatment Among Aging AdultsMultiple SclerosisSecondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Business StrategyConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology

Autoimmune DiseasesBiosimilarsDermatologyDiabetesEyecareLeukemia and LymphomaMental HealthObstetrics-Gynecology & Women's HealthOncologyOpioidsPediatricsPlaque PsoriasisSolid TumorsUrology

Expert InterviewsMedical World NewsPodcasts

Sponsored ResourcesSurveys

eNewsletterPrint Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Spotlight

AMCP
Autoimmune Diseases
Biosimilars
Cardiovascular Diseases
Eyecare
How to Reduce Maternal, Infant Health Risks During COVID-19
Improving Ophthalmic Care Access and Treatment Among Aging Adults
Multiple Sclerosis
Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

BusinessSee All >

Business Strategy
Consumers
Drug Costs
Drug Pipeline
Formulary
Health Management
Health/Disease Strategy
Hospitals & Providers
Industry Analysis
Pharmacy
Politics and Policy
Practice Management
Reimbursement
Technology

ClinicalSee All >

Autoimmune Diseases
Biosimilars
Dermatology
Diabetes
Eyecare
Leukemia and Lymphoma
Mental Health
Obstetrics-Gynecology & Women's Health
Oncology
Opioids
Pediatrics
Plaque Psoriasis
Solid Tumors
Urology

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2020 MJH Life Sciences^™ and Managed Healthcare Executive. All rights reserved.

Health plan liability in the hands of the Supreme Court

December 1, 2003

Outcome of ERISA interpretation will affect care management programs including drug utilization review